TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00094718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN/DEN4-3'delta30
Description: Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN/DEN4-3'delta30
Description: Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN/DEN4-3'delta30
Description: Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for WN/DEN4-3'delta30 vaccine
Study: NCT01247532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction - Cancer-Related Fatigue
Description: 7 week 2 hour class
Study: NCT06284616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASP-1
Description: patients following the Juvenile Arthritis Support Program at the Pediatric Rheumatology Clinic
Study: NCT02189499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
Description: Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
Study: NCT02863523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Behavioral Care
Description: Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
Study: NCT01120314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTAMIXABAN (XRP0673)
Description: Form: solution for injection~Route: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTAMIXABAN (XRP0673)
Description: Form: solution for injection~Route: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTAMIXABAN (XRP0673)
Description: Form: solution for injection~Route: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTAMIXABAN (XRP0673)
Description: Form: solution for injection~Route: intravenous
Study: NCT02798770

Intervention type: OTHER
Intervention: No Intervention Foreseen
Study: NCT01221025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
Study: NCT01344629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipin FDC
Description: Telmisartan80mg/Amlodipin5mg FDC
Study: NCT00729989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric suctioning
Description: The stomach will be suctioned shortly following birth with an orogastric tube
Study: NCT03198533

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon PA
Description: Implantation of Knee Prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon Pressfit
Description: Implantation of Knee Prosthesis
Study: NCT02255981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and massage
Description: Treatment consists in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.A total of 11 Chinese needles stainless steel, 25 x 40 were used by manual insertion and left for 12-15 minutes.~Periocular massage is taught and is practiced daily by the patient him or herself.
Study: NCT01604824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection in the abdomen
Study: NCT02650505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 43204 Vehicle
Study: NCT01344629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 80 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipin
Description: Amlodipin 5mg tablet
Study: NCT00900146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
Study: NCT00478244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Day -5 through Day -2: 50 mg/kg IV over 120 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Day -5 through Day -3: 25 mg/m2 IV over 60 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic bone marrow transplantation
Description: allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
Study: NCT01954745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
Study: NCT04366687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Parents - Safe and Healthy Kids
Description: Smart Parents - Safe and Healthy Kids (SPHSK) is a module designed to be added to existing evidence-based parent education programs. Because the module builds off of the core parenting skills developed in existing parent education programs, the module can be delivered in one session. SPSHK is comprised of three key CSA-prevention components: healthy child sexual development, parent-child communication about sex and sexual behaviors, and CSA-specific safety strategies such as vetting a babysitter and monitoring one-on-one time with adults. Behaviorally based, the module presents developmentally comprehensive information to parents of children 0-13 and utilizes role-playing scenarios and activities to maximize parents' use of learned skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parents as Teachers
Description: Parents as Teachers (PAT) is a parent-support program delivered to parents of children under five and focuses on improving parenting skills through parent-child interactions, development centered parenting, and general well-being. PAT has demonstrated positive effects on child and parent outcomes related to school readiness.
Study: NCT04030715

Intervention type: DRUG
Group type: OTHER
Intervention: bismuth-containing quadral therapy based on antibiotic susceptibility
Description: the different mucosal pathology graded by New Sydney System

Intervention type: DRUG
Group type: OTHER
Intervention: bismuth-containing quadral therapy based on antibiotic susceptibility
Description: the different mucosal pathology graded by New Sydney System
Study: NCT00233402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexvix
Description: Single Instillation, Transurethral Resection of the Bladder

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard white light cystoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard white light cystoscopy
Study: NCT01887171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
Study: NCT00900146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
Study: NCT01589718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen
Description: one intravitreal injection of Macugen prior to vitrectomy surgery

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
Study: NCT02723747

Intervention type: OTHER
Intervention: myocardial perfusion with magnetic resonance imaging
Study: NCT00900146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
Study: NCT01811303

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: D-fagomine
Description: Measure the changes produced on the postprandial Glycaemic response

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D-fagomine
Description: Measure the changes produced on the postprandial Glycaemic response
Study: NCT04326036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)
Description: Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol

Intervention type: DEVICE
Group type: OTHER
Intervention: Centricyte 1000
Description: Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV Deployment Of cSVF In Sterile Normal Saline IV Solution
Description: Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: IV Deployment Of cSVF In Sterile Normal Saline IV Solution
Description: Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
Study: NCT03564106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraarticular radiofrequency + intraarticular methylprednisolone
Description: intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)
Study: NCT04326036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liberase Enzyme (Roche)
Description: Sterile Collagenase Blend to separate cSVF from the AD-SVF

Intervention type: DRUG
Group type: OTHER
Intervention: Liberase Enzyme (Roche)
Description: Sterile Collagenase Blend to separate cSVF from the AD-SVF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline for Intravenous Use
Description: Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter

Intervention type: DRUG
Group type: OTHER
Intervention: Sterile Normal Saline for Intravenous Use
Description: Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
Study: NCT03001700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Serranator™ Alto PTA Serration Balloon Catheter
Description: The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
Study: NCT03564106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraarticular methylprednisolone
Description: intraarticular methylprednisolone (30 mg)
Study: NCT01955499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and/or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study: NCT03938285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theranova 400 membrane
Description: Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theranova 400 membrane
Description: Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FxCordiax 120 membrane
Description: Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FxCordiax 120 membrane
Description: Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
Study: NCT01144715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Mentor (TM) robotic stroke therapy device
Description: The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home Therapy Program
Description: Subjects in the control group will be instructed in a self administered home therapy program
Study: NCT03106987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator: Olaparib tablets
Description: Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria.
Study: NCT03035929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: A single dose of dexamethasone IV 4 mg will be administered.
Study: NCT02914860

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac CT
Description: * Cardiac CT - contract enhanced cardiac CT according to standard protocol~* D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~* Merge CT and D-SPECT image data to generate SUMO map.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac CT
Description: * Cardiac CT - contract enhanced cardiac CT according to standard protocol~* D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~* Merge CT and D-SPECT image data to generate SUMO map.
Study: NCT02428660

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Software-based drug & gene interaction risk analysis
Description: By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Software-based drug & gene interaction risk analysis
Description: By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.

Intervention type: OTHER
Group type: OTHER
Intervention: MTM
Description: Medication Therapy Management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTM
Description: Medication Therapy Management
Study: NCT02612792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Open flap debridement (OFD) alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
Study: NCT02428660

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MTM
Description: Medication Therapy Management
Study: NCT02278263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Given intravenously or topically
Study: NCT01047800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:~First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions~Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions.
Study: NCT02897752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait training with WA
Description: Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual gait training
Description: Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
Study: NCT03920267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study: NCT04798742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gluteus maximus transfer
Description: Gait analysis study of 15 patients with gluteus medius disruption

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gluteus maximus transfer
Description: Gait analysis study of 15 patients with gluteus medius disruption
Study: NCT02452853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HR
Description: HR:~HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
Study: NCT02612792

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement